TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene



Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline

Read More

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board





Company to Initiate Investigational Cardiovascular Study with Dr. Azimi and NanoStilbene


Read More

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers


Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

Read More

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board

Dr. James Veltmeyer to Assist Company in Expansion of Clinical Applications of Pterostilbene Based Therapeutics

Read More

StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein based vaccines.

SandBox Dental Labs, Inc. – is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio, Inc. – is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Nutraceutical Division – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.